Following the publication of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) paper “Transcriptomic Signatures in Sepsis and a Differential Response to Steroids: From the VANISH Randomized Trial”
https://www.atsjournals.org/doi/abs/10.1164/rccm.201807-1419OC PubMed: 30365341
We have demonstrated that sepsis response signatures (SRS)/sepsis endotypes are associated with different responses to treatment. Genome-wide gene expression profiling was performed and SRS endotype was determined using a previously established model with seven discriminant genes. We concluded that transcriptomic profile at onset of septic shock was associated with response to corticosteroids. Those with the immuno-competent SRS2 endotype had significantly higher mortality when given corticosteroids compared to placebo.